In vitro and in vivo gene transfer by an optimized α-cyclodextrin conjugate with polyamidoamine dendrimer

被引:136
作者
Kihara, F [1 ]
Arima, H [1 ]
Tsutsumi, T [1 ]
Hirayama, F [1 ]
Uekama, K [1 ]
机构
[1] Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 8620973, Japan
关键词
D O I
10.1021/bc025613a
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of the present study is to optimize the structure of the polyamidoamine starburst dendrimer (dendrimer) conjugate with alpha-cyclodextrin (alpha-CDE conjugate) as a nonviral vector. alpha-CDE conjugates of dendrimer (generation 3, G3) with various average degrees of substitution (DS) of alpha-CyD of 1.1, 2.4, and 5.4 were prepared. alpha-CDE conjugates formed the complexes with pDNA, resulting in a change of the particle sizes of pDNA complexes, but the distinction of physicochemical properties among their vector/pDNA complexes was only very slight. The membrane-disruptive ability of alpha-CDE conjugates on liposomes encapsulating calcein and their cytotoxicity to NIH3T3 and HepG2 increased with an increase in the DS value of alpha-CyD. In vitro gene transfer activity of alpha-CDE conjugates in both NIH3T3 and HepG2 cells augmented as the charge ratio (vector/pDNA) increased, and the activity of alpha-CDE conjugate (DS 2.4) was the highest at higher charge ratios among dendrimer (G3), the three alpha-CDE conjugates, and TransFast. After intravenous administration of pDNA complexes in mice, alpha-CDE conjugate (DS 2.4) delivered pDNA more efficiently in spleen, liver, and kidney, compared with dendrimer and other alpha-CDE conjugates (DS 1.1 and 5.4). The potential use of alpha-CDE conjugate (G3, DS 2.4) could be expected as a nonviral vector in vitro and in vivo, and these data may be useful for design of alpha-CyD conjugates with other nonviral vectors.
引用
收藏
页码:342 / 350
页数:9
相关论文
共 41 条
[31]   Substituted β-cyclodextrins interact with PAMAM dendrimer-DNA complexes and modify transfection efficiency [J].
Roessler, BJ ;
Bielinska, AU ;
Janczak, K ;
Lee, I ;
Baker, JR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (01) :124-129
[32]   From genes to gene medicines: Recent advances in nonviral gene delivery [J].
Rolland, AP .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1998, 15 (02) :143-198
[33]   CYCLODEXTRIN INCLUSION-COMPOUNDS IN RESEARCH AND INDUSTRY [J].
SAENGER, W .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1980, 19 (05) :344-362
[34]  
Song YK, 2002, METHOD ENZYMOL, V346, P92
[35]   A NOVEL HOST CONTAINING BOTH BINDING-SITE AND NUCLEOPHILE PREPARED BY ATTACHMENT OF BETA-CYCLODEXTRIN TO POLY(ETHYLENIMINE) [J].
SUH, JH ;
LEE, SH ;
ZOH, KD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (20) :7916-7917
[36]  
Szejtli J., 1982, CYCLODEXTRINS THEIR
[37]  
Szejtli J., 1988, CYCLODEXTRIN TECHNOL
[38]   FLUORESCENCE STUDIES ON THE MECHANISM OF LIPOSOME-CELL INTERACTIONS INVITRO [J].
SZOKA, F ;
JACOBSON, K ;
DERZKO, Z ;
PAPAHADJOPOULOS, D .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 600 (01) :1-18
[39]  
Thompson DO, 1997, CRIT REV THER DRUG, V14, P1
[40]   Cyclodextrin drug carrier systems [J].
Uekama, K ;
Hirayama, F ;
Irie, T .
CHEMICAL REVIEWS, 1998, 98 (05) :2045-2076